Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

The U.S. Food & Drug Administration (FDA) has granted Investigational New Drug (IND) regulatory clearance to initiate a Phase I/II clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, based on research by Dr. Eli Lewis of Israel's Ben-Gurion University of the Negev.

30 Jun 2010

Serotonin promotes beta cell expansion during pregnancy, offers possible cure for type 1 diabetes

Researchers funded by JDRF have discovered that the hormone, serotonin, may be involved in the increase of insulin-producing beta cells during pregnancy.

29 Jun 2010

Artificial pancreas holds promise for treating Type 1 diabetes

Shawna Wood would like nothing better than to go back to bed for another 24 hours of perfect blood sugar control. The 50-year old Wilsonville, Ore. woman has Type 1 diabetes, and she recently took part in a clinical trial of an automated replacement for her pancreas, which stopped producing insulin 9 years ago.

29 Jun 2010

Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes.

28 Jun 2010

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.

28 Jun 2010

UCSB, Sansum achieve milestone in JDRF funded Artificial Pancreas Project

The University of California Santa Barbara (UCSB) and Sansum Diabetes Research Institute (Sansum) announced today the achievement of a milestone in the Artificial Pancreas Project funded by the Juvenile Diabetes Research Foundation (JDRF).

28 Jun 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

The cause of diabetes during pregnancy is directly controlled by serotonin, a chemical produced by the body and normally known as a neurotransmitter, and is influenced by the amount of protein in the mother's diet early in pregnancy, according to new findings of an international team led by researchers at UCSF.

28 Jun 2010

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

St. Luke's Episcopal Hospital (St. Luke's) joins John Goss, M.D., in celebrating his milestone as he recently performed his 1,000th liver transplantation procedure. The largest liver transplant program in Houston's world-renowned Texas Medical Center, St. Luke's performs approximately 75 liver transplants annually. Additionally, St. Luke's liver transplant survival rate is the highest in the nation, with a one-year adult patient survival rate of 96.5 percent compared to the national expected survival rate of 89.38 percent.

24 Jun 2010

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for TOL101 (anti-TCR murine monoclonal antibody, type IgM), for treatment of recent onset immune-mediated Type 1 diabetes mellitus (T1DM). Designation is granted for treatment of patients sixteen years of age and younger with immune-mediated T1DM and preserved pancreatic beta-cell function, commonly referred to as juvenile diabetes.

23 Jun 2010

Insulin-producing beta cells can proliferate in patients recently diagnosed with type 1 diabetes: Researchers

Researchers from the Peninsula Medical School, working in collaboration with colleagues from Glasgow Royal Infirmary and the University of Brighton, have used a unique collection of pancreas specimens taken from patients who died soon after diagnosis of type 1 diabetes to show that they respond to the ongoing process of destruction by inducing their islet cells to proliferate.

15 Jun 2010

BMS employees across Canada taking part in third annual Community Action Day

More than 300 employees of Bristol-Myers Squibb Canada will get the day off from their regular work today, but they won't be taking it easy. Instead, they will be joining company retirees and members of their own families in helping out at a variety of community and charitable organizations as part of the company's third annual BMS Community Action Day.

11 Jun 2010

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Kineta, Inc. joined with The Iacocca Family Foundation today to announce a new investment partnership to speed development of Kineta's preclinical autoimmune drug candidate - ShK-186 - and its multiple applications to treat Type 1 diabetes mellitus.

7 Jun 2010

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Entelos, Inc. has announced a publication in the peer-reviewed journal Clinical and Experimental Immunology describing the Type 1 Diabetes (T1D) PhysioLab® platform, an in silico solution for rapidly streamlining preclinical research through the evaluation of alternative scenarios for therapeutic strategies.

2 Jun 2010

Juvenile Diabetes Research Foundation International honors Roche with "Chancellor's Award"

Roche, makers of ACCU-CHEK® blood glucose meters, infusion pumps, lancing devices and data management systems for people with diabetes, received the Juvenile Diabetes Research Foundation International's "Chancellor's Award" during the JDRF Annual Conference in Washington, D.C. The "Chancellor's Award" recognizes and honors longstanding JDRF corporate partners.

From Roche Sequencing and Life Science 2 Jun 2010

Researchers identify pattern of gene expression in kidney transplant recipients who don't need anti-rejection drugs

Researchers have identified a distinct pattern of gene expression in the largest reported group of kidney transplant recipients who have not rejected the transplant kidneys even though they stopped taking anti-rejection drugs. This finding may help identify other transplant recipients who could safely reduce or end use of immunosuppressive therapy. In 2008, more than 80,000 people in the United States were living with a kidney transplant.

31 May 2010

Novel imaging system helps visualize and monitor cellular immune responses of transplanted tissue in real time

A group of "color-coded" laboratory mice are providing researchers with a novel way of tracking T-cells, enabling them to visualize and monitor the cellular immune responses of transplanted tissue in real time. The new imaging system is described in the June issue of Nature Medicine, which appears on-line this week.

28 May 2010

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.

18 May 2010

New cases of Type 1 diabetes in young children to double by 2020: The Lancet

By 2020, new cases of Type 1 diabetes in children younger than five are expected to double if current trends continue, according to a study published in The Lancet. Diabetes is an epidemic, with numbers of those suffering from diabetes and its complications increasing worldwide.

14 May 2010

Castle Montessori Schools announce donation of $13,000 to JDRF Walk to Cure Diabetes

Castle Montessori Schools, a leader in Montessori education, believes it is their responsibility to contribute to the health and wellness of the community through active participation in local events and donations to charitable organizations. The schools proudly announce a donation of $13,000 to the Juvenile Diabetes Research Foundation "Walk to Cure Diabetes."

5 May 2010

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.

5 May 2010

Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

Serotonin promotes beta cell expansion during pregnancy, offers possible cure for type 1 diabetes

Artificial pancreas holds promise for treating Type 1 diabetes

Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

UCSB, Sansum achieve milestone in JDRF funded Artificial Pancreas Project

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Insulin-producing beta cells can proliferate in patients recently diagnosed with type 1 diabetes: Researchers

BMS employees across Canada taking part in third annual Community Action Day

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Juvenile Diabetes Research Foundation International honors Roche with "Chancellor's Award"

Researchers identify pattern of gene expression in kidney transplant recipients who don't need anti-rejection drugs

Novel imaging system helps visualize and monitor cellular immune responses of transplanted tissue in real time

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

New cases of Type 1 diabetes in young children to double by 2020: The Lancet

Castle Montessori Schools announce donation of $13,000 to JDRF Walk to Cure Diabetes

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Juvenile Diabetes News and Research

Latest Juvenile Diabetes News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in